Dyakov, I. N. Comparative clinical and economic evaluation of polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) in the 1<sup>st</sup> line therapy for adult patients with diffuse large B-cell lymphoma. ABV-press.
Chicago Style (17th ed.) CitationDyakov, I. N. Comparative Clinical and Economic Evaluation of Polatuzumab Vedotin in Combination with Rituximab, Cyclophosphamide, Doxorubicin and Prednisolone (R-CHP) in the 1<sup>st</sup> Line Therapy for Adult Patients with Diffuse Large B-cell Lymphoma. ABV-press.
MLA (9th ed.) CitationDyakov, I. N. Comparative Clinical and Economic Evaluation of Polatuzumab Vedotin in Combination with Rituximab, Cyclophosphamide, Doxorubicin and Prednisolone (R-CHP) in the 1<sup>st</sup> Line Therapy for Adult Patients with Diffuse Large B-cell Lymphoma. ABV-press.